Ultraviolet-B (UVB) irradiation is known to inhibit lymphocyte activity and consequently to reduce the incidence of graft-versus-host disease (GVHD) in experimental models for allogeneic bone marrow transplantation (BMT). GVHD is frequently associated with morbidity and mortality, but also with the beneficial graft-versus-leukemia (GVL) effect, demonstrated by a reduction in the incidence of leukemia relapse. In this study, we investigated whether UVB treatment of allogeneic T cells could prevent GVHD while sparing the beneficial GVL effect following allogeneic BMT in the Brown Norway myelocytic leukemia (BNML) rat model analogous to human acute myelocytic leukemia (AML). The dose of UVB required to abolish lethal GVHD in the rat allogeneic BMT model (WAG/Rij donors into BN recipients) was 4000 J/m 2 . However, this UVB dose simultaneously abrogated all GVL activity mediated by the T cells in the graft, while the radio-protective capacity of rat BM cells was strongly reduced. The number of allogeneic BM cells required to protect lethally irradiated BN rats was increased 50 to 100-fold. It is concluded that UVB acts as a non-selective form of T cell inactivation, and that UVB pretreatment of an allogeneic marrow graft is unlikely to be useful clinically as a preventive measure for GVHD, since other means of reduction of the number of functional T cells are less damaging to bone marrow stem cells. Keywords: ultraviolet-B; GVHD; GVL Allogeneic bone marrow transplantation (BMT) is being used with increasing frequency as a treatment for leukemia. A major complication of this treatment is severe or lethal graft-versus-host disease (GVHD). GVHD can be prevented by T cell depletion, 1 but this is frequently associated with an increase in the incidence of leukemia relapse. [2] [3] [4] These observations indicate that a graft-versus-leukemia
(GVL) effect is associated with GVHD and that removal of allo-reactive T cells from the graft to prevent GVHD diminishes the GVL activity. Results of several studies with murine models [5] [6] [7] [8] [9] and some clinical studies 2, 10 suggest that GVL can be separated from GVHD, but convincing evidence that GVL is a different type of GVH reaction has yet to be provided. It is most likely that a number of mechanisms exist which exert anti-leukemic activity (mediated by T cell subsets, NK cells and/or cytokines) and that some of these mechanisms simultaneously exert graft-versushost activity.
Ultraviolet-B (UVB) light is known to suppress lymphocyte activity and it has been shown to prevent GVHD while preserving hematopoietic reconstitution following BMT in mice 11, 12 and rats. 13, 14 Results obtained with animal model studies indicate that on the one hand UVB can overcome a major complication of T cell non-depleted allogeneic BMT by preventing GVHD, [11] [12] [13] [14] while on the other, UVB can inhibit immunogenicity, 15, 16 and therefore may prevent host-versus-graft disease or graft rejection, one of the problems in T cell-depleted BMT where adequate preconditioning is not performed. If allogeneic bone marrow is given as treatment for leukemia, it is not known, to date, whether UVB treatment of the bone marrow inoculum to prevent GVHD simultaneously inhibits the GVL reaction. It has been reported in experimental animals that UVB-irradiated bone marrow protects lethally irradiated animals. [11] [12] [13] [14] 17 However, in these studies an excess of bone marrow cells was grafted instead of limiting numbers of cells, 18 so that it remains uncertain to what extent UVB inactivates hematopoietic stem cells.
One of the major problems when trying to evaluate the effect of UVB in preventing GVHD is the difference in reported effective doses, ranging from 50 J/m 2 11 to 700 J/m 2 . 13, 17, 19 This is because many studies use lamps which emit across the broad spectrum of the UVB region (280-320 nm), and some have a low amount of emission in the biologically much more damaging UVC region (100-280 nm). Using broad-spectrum UVB lamps, the most biologically harmful regions are the shorter UVB wavelengths (280-300 nm). In this study we have used the Philips TL01 lamp, a virtually monochromatic lamp emitting at 312-313 nm. Our previous in vitro and in vivo studies using this lamp have shown that the most primitive rat hemopoietic stem cells do maintain a part of their colony-forming ability in contrast to the more mature stem cell subsets, at doses of UVB that abolish lymphocyte activity. 20 In the current study we wished to investigate three issues in view of a possible role for UVB irradiation of MHC mismatched allogeneic bone marrow grafts. Firstly, to establish at which dose of UVB GVHD could be prevented; secondly, to study the effect of the UVB treatment on the radioprotective capacity of the irradiated graft and, thirdly, to investigate whether a UVB treatment that abolished lethal GVHD simultaneously abrogated the GVL activity. If a GVL reaction could be retained without a concurrent GVHD this would indicate that different cell populations might be responsible for both phenomena and that UVB treatment of the bone marrow graft would offer a means of manipulating GVHD and GVL. This was assessed using the Brown Norway myelocytic leukemia (BNML) model, a well characterized rat leukemia model for human AML [21] [22] in which both GVHD and GVL have been studied extensively.
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Materials and methods
Animals
WAG/Rij (RT-1.A u ) and Brown Norway (BN, RT-1.A n ) inbred male rats, bred under specific pathogen-free conditions were purchased from the Harlan breeding facility at Rijswijk, The Netherlands, and used at age 10-14 weeks. They were housed in plastic cages, with food and water ad libitum.
Bone marrow transplantation (BMT)
Normal or leukemic recipient rats (BN) were lethally irradiated on day 0 of the experiment (10 Gy, dose rate 1 Gy/min) using ␥-irradiation from a Cesium source (Atomic Energy of Canada, Toronto, Canada). Leukemic rats were inoculated intravenously (i.v.) with 10 5 BNML cells 7 days prior to irradiation and allogeneic BMT. Donor bone marrow cells were obtained by flushing femora and tibiae of rats (WAG/Rij donors for allogeneic transplant, BN for syngeneic transplant) with Hanks' phosphate-buffered saline. The cells were passed through a sterile nylon filter to make a single cell suspension. Donor splenocyte suspensions were prepared in a similar fashion. Animals were transplanted 4-6 h after the irradiation with various numbers of BM cells, with or without graded numbers of splenocytes, by i.v. injection through the tail vein.
UVB irradiation of cells
Bone marrow cells or splenocytes were irradiated in a biohazard laminar air flow cabinet using a bank of 8 TL01 Philips lamps, (Eindhoven, The Netherlands) emitting UVB in a narrow wavelength band with a peak emission at 312 nm. The delivered dose was monitored using a specifically calibrated Waldman meter, type 585100 (Herbert Waldman & Co., Schwenningen, Germany). The meter was calibrated against two standards: (1) Model 742 UV visible spectro-radiometer, Optronic Laboratories, Orlando, FL, USA, and (2) Model Kipp E-11 thermopile, Kipp, Delft, The Netherlands. UVB irradiation conditions were optimized as previously described. 20 Cells were irradiated at a rate of 10 J/m 2 /s on a shaking platform (60 r.p.m.) in open petri dishes at a maximum nucleated cell density of 1 ϫ 10 7 /ml. The volume of 1 ml was 1 mm deep, and cells were maintained in RPMI medium on ice before, during and after irradiation. The dose ranged from 0 to 4000 J/m 2 . Control cells were sham-irradiated under the same conditions.
The BNML acute myelocytic leukemia model
The experiments were performed using the Brown Norway acute myelocytic leukemia model in the BN rat. Details of the model are described elsewhere. 21 The leukemia is transferred by i.v. injection of BNML cells derived from a leukemic spleen taken from a terminal stage leukemic animal. The ED 50 -L value for BNML cells (ie the number of cells required to induce leukemia in 50% of the animals) is 25 cells. For inocula in excess of 100 cells there is a log-linear relationship between the number of cells injected and the survival time. An increase in the survival time of 4 days correlates with a one log reduction in the leukemic cell load. This correlation is used to calculate the efficacy of a given treatment or for the estimation of the leukemic cell content in an inoculum containing an unknown number of leukemic cells.
Assessment of GVHD
GVHD was observed clinically by hair loss, skin lesions, diarrhoea, hunched posture and weight loss, and macroscopically at post-mortem by intestinal lesions and reduced liver and spleen weight. These symptoms accompanied lethal acute GVHD which was usually observed between 17 and 50 days post BMT. Experimental animals were observed for up to 150 days in case chronic GVHD should develop.
Assessment of GVL activity
Assessment of GVL activity was performed using a secondary recipient assay. Leukemic animals were treated with total body irradiation and given a BMT as described above and subsequently killed 15 days later. The total marrow content of one of the femurs from each BMT recipient was injected i.v. into the tail vein of an unconditioned secondary recipient BN rat. Thereafter, the secondary recipient was monitored for survival or time of death from leukemia. The survival time of this secondary recipient was used to calculate the leukemic cell content in the femur taken from the primary leukemic BMT recipient, using the established log-linear leukemic cell inoculation-survival time curve as described.
Assessment of radioprotection
Radioprotection was defined as survival to day 30 post BMT, provided the animals did not die at an earlier time point from GVHD. Death from aplasia was distinguished from GVHD at autopsy upon finding an acellular BM cavity (femur), a small spleen, with frequently a pale liver and bleedings from the nose and in the intestines.
Statistics
The effect of UVB irradiation on the radio-protective capacity of the BM was assessed by determining the ED 50 -BM values for BM cells exposed to UVB vs non-exposed control BM. Graded numbers of UVB irradiated BM cells (4000 J/m 2 ) or control BM cells were injected i.v. into lethally irradiated animals (10 animals/group) and from the number of animals surviving at 30 days after injection the ED 50 -BM values were derived using the probit analysis function of the SPSS statistical software program (SPSS, Inc, Chicago, IL, USA). To test the significance of differences in survival between the various groups in the GVHD experiments, Fisher's exact test was used.
Results
Prevention of GVHD after UVB treatment of the allogeneic graft
A T cell non-depleted human BMT inoculum contains 20-30% T cells, capable of initiating a considerable GVH reaction. In the WAG/Rij into BN rat model the BM inoculum contains, however, many fewer T cells (approximately 3%) which do not initiate detectable GVHD. 22 Therefore in the rat model, allogeneic BMT alone mimics human T celldepleted BMT. Thus, to simulate T cell non-depleted human allogeneic BMT, allogeneic donor spleen cells are routinely added as a source of T cells. An inoculum of 10 8 allogeneic BM cells will protect all lethally irradiated recipients. Addition of 1-2 ϫ 10 7 allogeneic spleen cells is required to induce lethal acute GVHD. 23 Thus, to analyse the capacity of UVB treatment to abolish GVHD, WAG/Rij BM cell suspensions were mixed with splenocytes prior to UVB treatment. Lethally irradiated BN rats were transplanted with UVB treated or non-UVB-treated 10 8 BM cells to which 1 ϫ 10 7 or 5 ϫ 10 7 splenocytes were added. Animals were monitored daily and, at death, autopsied to determine if GVHD or aplasia was the cause of death.
Addition of 10 7 splenocytes, representing a low dose of allogeneic spleen cells in this model, to 10 8 BM cells resulted in lethal GVHD in 43% of the animals (n = 14) with a median survival time of 33.5 days (Table 1A) When animals received a high dose of allogeneic splenocytes (5 ϫ 10 7 ) with their bone marrow transplant, the incidence of lethal GVHD increased accordingly (Table 1B) . All control animals (n = 15) died of acute GVHD with a median survival time (MdST) of 20 days. Differences between the non-treated and the various UVB-treated groups were tested for significance using Fisher's exact test. Previous irradiation of the inoculum with a low dose of UVB (2500 J/m 2 ) still resulted in lethal GVHD in 100% of the evaluable rats (P = 0.999) but the survival time was increased (MdST = 31 days). It has to be noted that the 4000 J/m 2 UVB dose in the second experiment resulted in an unexpectedly high incidence of graft failure (six out of eight rats). This contrasts with a graft failure in two of 21 rats in the other three 4000 J/m 2 UVB dose groups in the two experiments (Table 1A and B) . Thus, two rats were evaluable for the occurrence of lethal GVHD in experiment 2 and seven rats in experiment 1, ie nine rats in total. Irradiation of the inoculum with 2500 J/m 2 had no effect on the incidence of GVHD (12/12, 100%), 3000 J/m 2 reduced the GVHD incidence to 75% (9/12; P = 0.0752) whereas 4000 J/m 2 reduced the incidence of GVHD to 11% (1/9; P = 0.0001). In conclusion, 4000 J/m 2 UVB irradiation is the minimum dose that almost completely prevents lethal GVHD in allogeneic BMT recipients receiving a high dose of allogeneic T cells.
Effect of UVB treatment on the GVL reaction
The aim of the following experiment was to determine if GVL activity persisted after treatment of the inoculated T cells with a high dose (4000 J/m 2 ) of UVB that prevents lethal GVHD. Recipient BN rats were inoculated with 10 5 BNML cells, and 7 days later they were given a lethal dose (10 Gy) of TBI to induce a so-called state of 'minimal residual disease'. Recipient group A was given a syngeneic transplant of 3 ϫ 10 7 BN bone marrow cells. Group B was given an allogeneic (WAG/Rij) BMT of 3 ϫ 10 7 BM cells alone (adequate for radioprotection in 100% control animals), while groups C and D were treated with allogeneic BMT plus 2 ϫ 10 7 allogeneic splenocytes (adequate to induce lethal GVHD in 100% controls), unmanipulated (group C) or treated with 4000 J/m 2 UVB (group D). From each experimental group, six primary recipient animals were monitored for survival following treatment. All animals receiving a syngeneic BMT, allogeneic BMT alone or allogeneic BMT plus UVB-treated splenocytes (groups A, B, D) died of leukemia relapse with a median survival time (MdST) of 31, 33.5 and 34 days post BMT, respectively (Figure 1 ). Animals receiving allogeneic BMT plus unmanipulated splenocytes (group C) died from lethal GVHD as expected, with a MdST of 17.5 days, and with no visible signs of leukemia relapse. These data suggest that UVB irradiation abrogates both the GVHD and GVL reaction.
At 15 days post BMT when animals showed clinical symptoms of GVHD, four primary recipients of each group were killed, and a total femoral bone marrow cell content from each primary recipient was injected into a normal secondary BN recipient. The development of leukemia as well the survival times of the secondary recipients were recorded ( Table 2 ). The log-linear survival time-leukemic cell number relationship was used to calculate the number of leukemic cells present in the injected BM cells from one femur of the primary allogeneic BMT recipient. Shorter survival times indicate higher numbers of leukemic cells inoculated. This allowed comparison of the anti-leukemic activity of syngeneic, allogeneic (with few T cells), allogeneic T cellcontaining and allogeneic UVB irradiated T cell-containing BM grafts. Secondary recipients of BM cells from group Table 1 Influence of UVB irradiation of the BM graft on the prevention of GVHD following addition of (A) Animals were treated with lethal TBI (10 Gy ␥-irradiation) and transplanted with 10 8 allogeneic BMC + (A) 1 × 10 7 and (B) 5 × 10 7 splenocytes UVB irradiated simultaneously, or with non-UVB irradiated splenocytes in the control groups. NR = not reached after 150 days follow-up. A all died of leukemia between days 25 and 27 after the secondary transplantation (Table 2) , corresponding to a leukemic cell load of approximately 10 6 cells per femur (Table  2) at the time of sacrifice on day 15 post BMT. There was an increase in the survival time of secondary recipients in group B (MdST = 32 days), compared to group A (MdST = 27 days). This indicates a modest GVL activity exerted by the low numbers of T cells present in allogeneic BM. The increase in MdST of 5 days in group B indicates approximately a one log decrease in the number of leukemic cells in the femurs of animals treated with allogeneic BMT compared to syngeneic BMT.
Secondary recipients of BM plus non-irradiated allogeneic splenocytes from group C died between days 45 and 55, while in one out of four animals no leukemia developed. It was calculated that the inocula, ie the femurs of the primary recipients, contained less than 100 leukemic cells. This demonstrates a significant GVL activity exerted by the added T cells amounting to an additional three log cell kill compared to the allogeneic BMT only group. The secondary recipient animals from group D, transplanted with allogeneic BM plus UVB-irradiated splenocytes, died of leukemia between days 25 and 38 (MdST = 31 days), at the same time as animals in group B. This clearly demonstrates that there is no additional GVL effect yielded by UVBtreated splenocytes when compared to the allogeneic BMT only group, and that UVB treatment completely abrogates the potential GVL effect of the added allogeneic T cells. Primary leukemic BMT recipients were pretreated with lethal TBI and allogeneic BMT Ϯ additional splenocytes Ϯ UVB irradiation. Fifteen days after the primary BM transplant, the recipients were killed and the total content of one femur from each primary recipient was injected into one secondary recipient. The secondary recipients were monitored for death from leukemia. The survival time of the secondary recipient is directly correlated to the number of leukemic cells in the femur content in the primary recipient. Shorter survival times indicate higher numbers of injected leukemia cells.
Effect of UVB treatment on radioprotective capacity of BM cells
To quantify the UVB-induced damage to the radioprotective capacity of BM stem cells, the ED 50 -BM value in the allogeneic setting was determined. The ED 50 -BM value for BMT is defined as the number of bone marrow cells required to protect 50% of lethally irradiated animals. Lethally irradiated BN rats received graded numbers of unmanipulated or UVB-irradiated (4000 J/m 2 ) WAG BM cells. In the unmanipulated allogeneic controls, 90% (n = 10) animals died of aplasia following transplantation with 10 6 BM cells ( Figure 2) ; only 20% allogeneic BMT recipients died if the cell dose was 3 ϫ 10 6 BM cells. No animals died in the groups receiving higher numbers of BM cells. From these results, the ED 50 -BM value in the control groups was calculated to be 1.93 ϫ 10 6 BM cells. In contrast, all animals receiving 3 ϫ 10 7 UVB irradiated BM cells, at a dose of 4000 J/m 2 which is sufficient to abrogate GVHD, died of aplasia. Inocula containing as high as 9 ϫ 10 8 UVBirradiated BM cells only protected 90% of the lethally irradiated animals. The ED 50 -BM value following highdose UVB was calculated to be 1.28 ϫ 10 8 BM cells. These results demonstrate that between 50 and 100 times more BM cells are required for radioprotection when the cells have been treated with 4000 J/m 2 UVB prior to inoculation.
Discussion
It is well established that T cell depletion of allogeneic BM grafts can prevent GVHD, but simultaneously increases the risk of leukemia relapse. 1,2 UVB light has been suggested as an alternative approach to GVHD prophylaxis in allogeneic BMT. In this study, we used a rat leukemia model and examined whether UVB treatment of allogeneic BM grafts containing T cells could prevent GVHD while sparing the beneficial GVL effect exerted by the allogeneic T cells. In the BN rat transplantation model engraftment was ensured by admixing sufficient non-irradiated normal bone marrow cells to the irradiated splenocytes. Infusion of low numbers of T cells (1 ϫ 10 7 splenocytes, Table 1A ) gave rise to lethal GVHD in 40-50% of the rats and prior treatment of BM and splenocytes with 3000 J/m 2 UVB can be used as a form of GVHD prophylaxis. However, significant lethal GVHD resulted if the same UVB schedule was applied to animals receiving higher numbers of T cells (5 ϫ 10 7 , Table 1B ). When animals received the higher dose of splenocytes which induced GVHD in 100% of control animals, a dose of 4000 J/m 2 was necessary for GVHD prophylaxis.
There is a good correlation between the dose of UVB reported here to be necessary for GVHD prophylaxis and the inhibition of clonal T cell expansion in vitro. 20 In our previous studies, we found that a dose of 3000 and 4000 J/m 2 reduced the number of clonal T cells to 30% and 1% of the control value, respectively. When the animals received 5 ϫ 10 7 splenocytes, the in vitro results predict that this corresponded to an inoculum of 1.6 ϫ 10 7 and 1 ϫ 10 5 viable T cells, respectively. Lethal GVHD was seen in 75% of animals in the 3000 J/m 2 group, whereas this was reduced to 11% in the group treated with 4000 J/m splenocytes is too few to induce GVHD or a GVL reaction. 23 Combining these in vitro and in vivo results, we conclude that in vitro assays can be useful in predicting the incidence of lethal GVHD in vivo.
What is the effect of UVB on the GVL activity? While in humans it appears that GVL can occur in the absence of clinical GVHD if a sufficiently low dose of T cells is used to treat relapsed CML, 24, 25 previous studies in this animal model have indicated that GVHD and GVL are inseparable and represent the same phenomenon. 26 Our results in the present study support this assertion. Significant GVHD and GVL activity were observed in animals receiving BMT with unmanipulated splenocytes while elimination of GVHD by prior treatment of BM and splenocytes with UVB resulted in a complete loss of GVL activity. These results imply that either: (1) GVH and GVL activities are mediated by the same population of T cells through the same mechanism (ie GVL and GVH are the same phenomenon); (2) GVH and GVL activities are mediated by the same cells but through different mechanisms and both mechanisms are susceptible to UVB-induced damage; (3) GVH and GVL activities are mediated by different populations of cells but both populations are equally susceptible to damage by UVB irradiation. The damage could be UVB-induced loss of the proliferative potential of T cells or a reduction in cytokine production as cytokines may be effectors in the induction of the GVHD/GVL effect. Cytokine production or interleukin release 27 are more frequently reported to be increased rather than decreased by cells which have been previously exposed to UVB.
It has also been reported that dendritic cells are particularly sensitive to UVB-induced damage 19 and anergy may be induced by the inactivation of these antigen presenting cells. Cytotoxic T lymphocytes (CTL) and natural killer (NK) cells have also in some cases been implicated in GVL activity. 5, 8, 28 We have shown in previous in vitro studies 20 that a significant proportion of the cytotoxic activity of these cells is maintained after treatment with up to 4000 J/m 2 UVB, although it is unlikely that any new cytotoxic activity can be generated. However, since we did not see any significant GVL activity in our in vivo experiments in the absence of GVHD, it appears that if the UVBtreated splenocytes did maintain cytotoxic activity, they did not exert any measurable effect on the leukemic cells in vivo. In humans, it is sometimes hypothesized that when GVL activity is observed in the absence of GVHD, that this is actually a sub-clinical GVHD phenomenon. Although the results in this animal model support the idea that GVL exists only as clinical or sub-clinical GVHD, it was demonstrated using another animal model 9 that GVL could exist in the absence of GVHD. It may be beneficial in the future to look at the effect of UVB on GVL activity in such a model.
A third consideration in assessing the potential of UVB is its effect on the radioprotective capacity of BM cells. Using the ED 50 -BM assay, we observed that the dose of 4000 J/m 2 , required for effective abolition of GVHD, induced a two log reduction in the number of radioprotective cells in the BM inoculum (Figure 2 ). Our previous in vitro studies suggest that UVB irradiation damages the cells with short-term repopulating ability (STRA cells) which are crucial for early radioprotection, to a larger extent than the cells with long-term repopulating ability (LTRA). 20 Day 8 colony-forming unit spleen (CFU-S) assays, which measure more mature hematopoietic progenitor cells only capable of short-term radioprotection, 29 showed 1% survival of CFU-S after irradiation with 4000 J/m 2 . In contrast, the cobblestone area-forming cell (CAFC) assay, which measures stem cells associated with both STRA and long-term repopulating ability (LTRA cells) [30] [31] [32] [33] showed that LTRA cells were less sensitive than STRA cells to UVB-induced damage. 20 The approximate two log reduction in the ED 50 -BM value following high dose (4000 J/m 2 ) UVB irradiation is in the same order of magnitude as the 1% survival of the day 8 CFU-S. It is most likely that the animals in this experiment died before the less mature stem cells (comprising the stem cells with LTRA) were able to generate sufficient numbers of new functional cells of the various hematopoietic lineages.
In conclusion, we have shown that it is possible to abolish GVHD following allogeneic BMT by UVB irradiation of the graft. We have demonstrated for the first time, using a sensitive in vivo assay system, that the dose of UVB required to abolish GVHD simultaneously abrogates all GVL activity. However, a two log cell kill is required to sufficiently prevent GVHD, and the dose of UVB which effects this reduction of lymphocytes also exerts a two log cell kill of STRA cells and a 75% kill of LTRA cells. Given the fact that any new procedure to prevent GVHD should not damage a significant proportion of radioprotective cells UVB iradiation is not the treatment of choice. We conclude that UVB treatment is a crude form of T cell inactivation that has no advantage over conventional physical methods of T cell depletion. In addition, at the dose level needed to inactivate T cells UVB is extremely damaging to radioprotective BM cells.
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